CG Oncology vs TScan Therapeutics
CGON and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGON and TCRX compare
CG Oncology is the larger company, worth 764 times as much as TScan Therapeutics ($7.5B against $9.8M).
CG Oncology grew revenue faster over the last twelve months (184% versus 2.2% for TScan Therapeutics).
TScan Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1655% compared with −3851% at CG Oncology.
CG Oncology scores higher on the StockData Score (5 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGON | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | $7.5B | $9.8M |
| Share price | $84.78 | $0.145 |
| Change, 1 year | 125% | −87.2% |
| Change, 5 years | – | −98.3% |
| Beta (5Y) | 0.24 | 2.20 |
| Employees | 142 | 142 |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1219× | 1.4× (better) |
| P/B | 7.6× | 0.1× (better) |
| FCF yield | −2.5% (better) | −1204% |
| Fair value | – | $1.36 |
| Margin of safety | – | 89.3% |
| Growth | ||
| Revenue growth (TTM) | 184% (better) | 2.2% |
| Revenue growth, 5Y average | – | 56.9% |
| Profitability | ||
| Operating margin | −4294% | −1695% (better) |
| Net margin | −3851% | −1655% (better) |
| FCF margin | −3068% | −1666% (better) |
| Return on equity | −28.3% (better) | −95.8% |
| Return on invested capital | −2103% | – |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.47 |
| Interest coverage | – | −43.2× |
| Current ratio | 21.70 (better) | 3.37 |
| Altman Z-score | 80.45 (better) | −6.31 |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Buyback yield | −6.5% | – |
| Shareholder yield | −6.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 106% | 53.5% |
| Held by insiders | 17.3% | 32.8% |
| Insider net buying, 12 months | $20.0M (better) | $146K |
| Short interest, % of float | 12.6% | 4.4% |
Go deeper
- CGON stock overview
- CGON income statement
- CGON valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.